Press "Enter" to skip to content

Government prohibits distribution, sale of Buclizine as ‘appetite stimulant’

The drug will, however, be allowed to be marketed for "symptomatic treatment of various allergic conditions (rhinitis, conjunctivitis and urticaria) and for prevention and treatment of motion sickness."

Original source:

Also Read:   Glenmark initiates Phase 3 clinical trials on Favipiravir to check efficacy on COVID-19 patients